comparemela.com
Home
Live Updates
Positive Dupixent® (dupilumab) Phase 3 Data in Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis Published in The Lancet : comparemela.com
Positive Dupixent® (dupilumab) Phase 3 Data in Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis Published in The Lancet
/PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that The Lancet has published positive results from a Phase 3...
Related Keywords
Japan ,
Paris ,
France General ,
France ,
Walterj Hamlin ,
Georged Yancopoulos ,
Amys Paller ,
Regeneron Velocimmune ,
Prnewswire Regeneron Pharmaceuticals Inc ,
Regeneron Pharmaceuticals Inc ,
Twitter ,
Regeneron Genetics Center ,
Drug Administration ,
Dupilumab Development Program ,
Regeneron Velocimmune Technology ,
Nasdaq ,
Northwestern University Feinberg School Of Medicine ,
Teva Pharmaceutical Industries Ltd ,
Exchange Commission ,
European Union ,
European Medicines Agency ,
Euronext ,
European Medicines ,
Northwestern University Feinberg School ,
Global Assessment ,
Eczema Area ,
Severity Index ,
Patient Oriented Eczema Measure ,
Atopic Dermatitis ,
Dermatology Life Quality Index ,
Infant Dermatitis Quality ,
Life Index ,
Dermatitis Family Impact ,
Chief Scientific Officer George ,
Prescribing Informationincluding Patient ,
Regeneron Genetics ,
Forward Looking Statements ,
Regeneron Pharmaceuticals ,
Product Candidates ,
Teva Pharmaceutical Industries ,
comparemela.com © 2020. All Rights Reserved.